Merck Buys Verona Pharma For $10 Billion To Expand COPD Portfolio

Merck is acquiring Verona Pharma, a biotech firm specializing in respiratory diseases, in a deal worth approximately $10 billion, Michelle Chapman reported for the Associated Press (AP).

Merck’s commercial reach and clinical expertise will help accelerate Ohtuvayre’s rollout and impact. I Photo: Coolcaesar Wikimedia Commons

With the purchase, Merck gains access to Verona’s FDA-approved COPD drug, Ohtuvayre, which was approved in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.

“Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardiopulmonary diseases while delivering near- and long-term growth and value for shareholders,” Merck Chairman and CEO Robert Davis said.

Verona CEO David Zaccardelli noted that Merck’s commercial reach and clinical expertise will help accelerate Ohtuvayre’s rollout and impact.

The deal has been approved by both companies’ boards and is expected to close in the fourth quarter, pending shareholder approval and final court sanction from the High Court of Justice of England and Wales.